Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short-Term Debt repayments (2021 - 2023)

Amphastar Pharmaceuticals has reported Short-Term Debt repayments over the past 4 years, most recently at $125.0 million for Q2 2023.

  • Quarterly results put Short-Term Debt repayments at $125.0 million for Q2 2023, changed N/A from a year ago — trailing twelve months through Jun 2023 was $125.4 million (changed N/A YoY), and the annual figure for FY2021 was $1.2 million, changed.
  • Short-Term Debt repayments for Q2 2023 was $125.0 million at Amphastar Pharmaceuticals, up from $387000.0 in the prior quarter.
  • Over the last five years, Short-Term Debt repayments for AMPH hit a ceiling of $125.0 million in Q2 2023 and a floor of $387000.0 in Q3 2021.